New DIR Fee Transparency Rule

New DIR Fee Transparency Rule

At NCODA, we are committed to empowering and educating all stakeholders in oncology care. With the recent implementation of the DIR Fee Transparency Rule, NCODA is actively engaging our professional community of leaders and passionate healthcare providers to bring...
SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

SpringWorks Therapeutics Announces FDA Approval of OGSIVEO™ (nirogacestat) as the First and Only Treatment for Adults with Desmoid Tumors

– Approval based on positive data from Phase 3 DeFi trial, in which OGSIVEO significantly improved progression-free survival and objective response rate, with rapid and sustained improvements in pain, physical functioning and overall quality of life – STAMFORD, Conn.,...